

Product datasheet for TL515020V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Ikbkg Mouse shRNA Lentiviral Particle (Locus ID 16151)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Ikbkg Mouse shRNA Lentiviral Particle (Locus ID 16151)

Locus ID: 1615

Synonyms: 1110037D23Rik; Al848108; Al851264; AW124339; IKK[g]; NEMO

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: Ikbkg - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: BC021431, NM 001136067, NM 001161421, NM 001161422, NM 001161423, NM 001161424,

NM 010547, NM 178590, NM 001161424.1, NM 010547.1, NM 010547.2, NM 178590.1,

NM 178590.2, NM 178590.3, NM 178590.4, NM 001136067.1, NM 001136067.2,

NM 001161421.1, NM 001161422.1, NM 001161423.1, BC026905

UniProt ID: 088522

Summary: Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B

thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Its binding to scaffolding polyubiquitin seems to play a role in IKK activation by multiple signaling receptor pathways. Also considered to be a mediator for TAX activation of NF-kappa-B. Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Involved in TLR3- and IFIH1-mediated antiviral innate response; this function

requires 'Lys-27'-linked polyubiquitination.[UniProtKB/Swiss-Prot Function]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).